Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Jun 10;345(8963):1479-80.
doi: 10.1016/s0140-6736(95)91038-7.

Replacement therapy with imiglucerase for type 1 Gaucher's disease

A Zimran  1 , D Elstein, E Levy-Lahad, S Zevin, I Hadas-Halpern, Y Bar-Ziv, J Foldes, A J Schwartz, A Abrahamov
Affiliations
Clinical Trial

Replacement therapy with imiglucerase for type 1 Gaucher's disease

A Zimran et al. Lancet. .

Abstract

Gaucher's disease, the most common sphingolipidosis, is caused by deficiency of the lysosomal enzyme glucocerebrosidase. Therapy with alglucerase (the placental enzyme) is safe and effective at various dosing regimens. We report the use of low-dose imiglucerase (the recombinant enzyme) at two dosing schedules: 15 u/kg once fortnightly or 2.5 u/kg thrice weekly. Mean reductions in spleen and liver volumes achieved (in all ten patients) by imiglucerase at 12 months were 36.4% and 14.5%, respectively; mean increase in haemoglobin and platelet counts were 13.4% and 25.7%. There were no serious side-effects. No significant differences were observed between the two schedules. Low-dose low-frequency imiglucerase may be an alternative cost-effective approach with satisfactory clinical response and uncompromised quality of life.

PubMed Disclaimer

Comment in